Arkadios Wealth Advisors Has $1.07 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Arkadios Wealth Advisors boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 398.8% in the second quarter, Holdings Channel reports. The firm owned 2,040 shares of the biopharmaceutical company’s stock after purchasing an additional 1,631 shares during the period. Arkadios Wealth Advisors’ holdings in Regeneron Pharmaceuticals were worth $1,071,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of REGN. World Investment Advisors boosted its holdings in shares of Regeneron Pharmaceuticals by 51.7% in the second quarter. World Investment Advisors now owns 549 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 187 shares during the period. Flagship Harbor Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $467,000. Evergreen Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 84.6% in the second quarter. Evergreen Wealth Management LLC now owns 10,436 shares of the biopharmaceutical company’s stock valued at $5,479,000 after buying an additional 4,783 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $31,000. Finally, New York Life Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 0.8% in the second quarter. New York Life Investment Management LLC now owns 14,353 shares of the biopharmaceutical company’s stock valued at $7,535,000 after buying an additional 113 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a report on Wednesday. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Bank of America increased their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.36.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $651.80 on Friday. The firm has a market capitalization of $69.08 billion, a PE ratio of 15.61, a PEG ratio of 2.03 and a beta of 0.31. The company’s 50-day moving average is $581.80 and its 200-day moving average is $565.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $883.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm earned $12.46 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.